The first DTx Asia conference was held in Seoul, South Korea last week where experts engaged in dialogues surrounding the penetration, regulatory, and reimbursability environment around digital health solutions in the APAC region.  Wellthy’s CEO and Co-founder, Abhishek Shah, was a co-chair at the event and part of a panel on “How DTx companies plan

Digital therapeutics are taking off but are they meeting the needs of all stakeholders? Due to pharma’s vast size and their desire to ‘test and learn’ they often create multiple DTx ‘point solutions’ which leads to issues not just for themselves but also for other stakeholders. Patients  May have multiple comorbidities therefore experience ‘Digital poly-pharmacy’

Where Big Pharma Stands Recognizing this need, the major players in the PAH treatment space have added a digital solution to their portfolio. This first wave of solutions provide tracking of symptoms, education on the disease, interaction with devices such as nebulizers, and monitoring of emotional wellbeing. There is still an opportunity to go deeper

Introduction More than half the people die within the first year of being diagnosed with Lung Cancer. The American Cancer Society’s estimates for lung cancer in the United States for 2022 are about 236,740 new cases and about 130,180 deaths. Lung Cancer is directly responsible for loss of income, increased health-related costs, morbidity, and mortality